61![SAMHSA Opioid Overdose Toolkit SAMHSA Opioid Overdose Toolkit](https://www.pdfsearch.io/img/93bb13422b6765c16f76a0c27eefefc7.jpg) | Add to Reading ListSource URL: atf3.clincocommunicat.netdna-cdn.comLanguage: English - Date: 2014-10-18 09:09:10
|
---|
62![PHE377: A novel clinical-stage TRPV1 antagonist devoid of “class” side effects for the treatment of chronic pain syndromes Summary of the Opportunity PharmEste wishes to identify a partner for development and commerc PHE377: A novel clinical-stage TRPV1 antagonist devoid of “class” side effects for the treatment of chronic pain syndromes Summary of the Opportunity PharmEste wishes to identify a partner for development and commerc](https://www.pdfsearch.io/img/ce7dbe0ab0d69a9b6a32750b22c99a28.jpg) | Add to Reading ListSource URL: www.pharmeste.comLanguage: English - Date: 2012-11-09 04:33:07
|
---|
63![](https://www.pdfsearch.io/img/936ce40ba9357e18e1fd9647be164b2b.jpg) | Add to Reading ListSource URL: www.tnfamilymedicine.comLanguage: English - Date: 2015-02-27 23:15:26
|
---|
64![Writing a Prescription INDICATION EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. EVZIO i Writing a Prescription INDICATION EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. EVZIO i](https://www.pdfsearch.io/img/ed2958ca628103c16534a92d10e3e4d7.jpg) | Add to Reading ListSource URL: prescribetoprevent.orgLanguage: English - Date: 2015-04-22 16:01:30
|
---|
65![P11444 - ASCO2014 MEC and HEC P11444 - ASCO2014 MEC and HEC](https://www.pdfsearch.io/img/f51a6b47787edf6b75f345c00224e614.jpg) | Add to Reading ListSource URL: www.tesarobio.comLanguage: English - Date: 2014-05-30 11:29:44
|
---|
66![A D D I C T I O N T R E A T M E N T Forum THE QUARTERLY NEWSLETTER FOR CLINICAL HEALTH CARE PROFESSIONALS ON ADDICTION TREATMENT A D D I C T I O N T R E A T M E N T Forum THE QUARTERLY NEWSLETTER FOR CLINICAL HEALTH CARE PROFESSIONALS ON ADDICTION TREATMENT](https://www.pdfsearch.io/img/c899a9079fd8548cf3d6a3faa9a03130.jpg) | Add to Reading ListSource URL: atforum.comLanguage: English - Date: 2013-03-01 14:06:33
|
---|
67![P11444 - ASCO2014 MEC and HEC P11444 - ASCO2014 MEC and HEC](https://www.pdfsearch.io/img/55983f4f00a4962473f3eb129d7107ef.jpg) | Add to Reading ListSource URL: www.tesarobio.comLanguage: English - Date: 2014-05-30 11:29:54
|
---|
68![OTC Savings Drug List Because many medications are available over the counter (OTC), your plan does not cover certain prescription allergy treatment drugs and stomach disorder drugs that have OTC alternatives unless your OTC Savings Drug List Because many medications are available over the counter (OTC), your plan does not cover certain prescription allergy treatment drugs and stomach disorder drugs that have OTC alternatives unless your](https://www.pdfsearch.io/img/36822a68d96b0369f0a29e524556e020.jpg) | Add to Reading ListSource URL: www.bcbst.comLanguage: English - Date: 2015-03-31 08:47:10
|
---|
69![HEART FAILURE (HF) DISCHARGE ORDERS Page 1 of 1 Post Office Box 2168 Carson City, Nevada HEART FAILURE (HF) DISCHARGE ORDERS Page 1 of 1 Post Office Box 2168 Carson City, Nevada](https://www.pdfsearch.io/img/b0e117659ecc6a5517be8e0566d31ab9.jpg) | Add to Reading ListSource URL: www.carsontahoe.comLanguage: English - Date: 2012-06-18 12:40:30
|
---|
70![Astellas Receives Approval for a Supplemental New Drug Application for Irribow®/Irribow® OD, a Treatment of Diarrhea-predominant Irritable Bowel Syndrome, in Japan Tokyo, May 26, Astellas Pharma Inc. (“Astella Astellas Receives Approval for a Supplemental New Drug Application for Irribow®/Irribow® OD, a Treatment of Diarrhea-predominant Irritable Bowel Syndrome, in Japan Tokyo, May 26, Astellas Pharma Inc. (“Astella](https://www.pdfsearch.io/img/a0b61fc4be7b17d588a7d68d10f59eae.jpg) | Add to Reading ListSource URL: www.astellas.comLanguage: English - Date: 2015-05-26 01:47:13
|
---|